在膜性腎病症中,用利圖西瑪和低劑量環胺和普雷德尼松的組合治療
Coralien H Vink1, Jack F M Wetzels1, Anne-Els van de Logt1
1Department of Nephrology, Radboud institute of Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Kidney international reports
|December 19, 2024
概括
低剂量三重疗法在大多数膜性病患者中有效诱导免疫学和临床缓解. 早期监测抗PLA2R抗体水平可以识别那些需要加强治疗的患者,以获得更好的结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 使用环胺 (CP) 或修复剂 (RTX) 治疗膜性病 (MN) 的标准治疗方法显示效率低于最佳水平.
- 患有MN的高风险患者通常对抗PLA2R抗体 (PLA2Rab) 呈阳性.
研究的目的:
- 在高风险的PLA2Rab阳性MN患者中评估低剂量三重治疗方案 (RTX,CP,普德尼松) 的疗效.
- 分析PLA2Rab水平的动力学及其与临床和免疫学缓解的相关性.
主要方法:
- 一个单臂前性队列研究,涉及26名高风险PLA2Rab阳性MN患者.
- 治疗包括修改后的RTX,CP和普德尼松低剂量疗法.
- 定期测量PLA2Rab水平,血清肌素,白蛋白和尿蛋白与肌素比率 (uPCR).
主要成果:
- 88%的患者在8周内实现了免疫缓解 (IR).
- 21名患者在初始治疗后实现了蛋白尿症缓解;所有需要重复治疗的7名患者都有反应.
- 较高的PLA2Rab基线标位和较长的PLA2Rab半衰期 (T1/2) >7天与缺乏反应和需要额外治疗有关.
- 4名患者发生了严重的不良事件;大多数不良事件是轻微的,白血病是最常见的.
结论:
- 低剂量三重疗法在大多数高风险的MN患者中迅速诱导IR和CR.
- 早期评估PLA2Rab水平 (2-4周) 可以确定需要更强化治疗策略的患者.
- 这种方法提供了一个有前途的替代方案,用于管理膜性病的挑战性病例.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


